July 21, 2010 7:31 AM | 1 min read
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
According to Goldman Sachs, Johnson & Johnson (NYSE: JNJ) was highlighted with risk as it headed into it's 2Q due to $0.11 below consensus rating and potential management guidance reduction for 2010 due to cost-restructuring challenges. Goldman has maintained Johnson & Johnson at "neutral".The key risks involved are (a) pharma pipeline delays, (b) collateral brand damage due to Consumer recall, and (c) EU pricing pressures. The upside risks are (a) pipeline approvals, and (b) cost restructuring benefits. Goldman says Abbott Laboratories (NYSE: ABT) is the preferred diversified pharma company, expected to have higher quality 2Q earnings, lesser risk in reducing 2010 guidance, and a discounted 2011 PEG due to superior EPS growth. Stock prices yesterday quoted at $58.58.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.